MARLBOROUGH, Mass., June 6, 2019 /PRNewswire/ — Garden Remedies, Inc. (GRI), Massachusetts’ only cannabis company founded and led by a woman physician, is pleased to announce that their newest dispensary, located at 416 Boston Post Road East in Marlborough, just received final approval to commence adult use retail operations from the Massachusetts Cannabis Control Commission (CCC). Garden Remedies Marlborough will officially open for adult use cannabis sales in Marlboro Square this Sunday, June 9, 2019 from noon to 5 p.m. Appointments are not required.
Les membres permettront au plus grand organisme de recherche scientifique du gouvernement de demeurer à l’avant-garde
Members will keep Government’s largest science and research organization ahead of the curve
We care about people, communities, Canada. We care about our world.
– CannTrust We Care Philosophy
— Establishes the Company’s retail footprint in the US with the integration of The Apothecarium’s operations (including all employees)
Cresco Capital Partners Raises $60M in Oversubscribed Cannabis Private Equity Fund
Mera Cannabis Corp. launches rebrand in light of expansion domestically and abroad
CORONA, Calif., June 6, 2019 /PRNewswire/ — Micro Lab Farms, a premier provider of fully automated turnkey systems for rapid production of legal cannabis, announced that it is offering four different units designed for specific applications.
TORONTO, June 6, 2019 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV:PCLO), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has entered into a scheme implementation agreement (the “Implementation Agreement”) pursuant to which PharmaCielo has agreed to acquire all of the issued and outstanding shares and listed options of Creso Pharma Ltd. (“Creso Pharma”) (ASX:CPH), for an aggregate purchase price of approximately A$122 million (the “Acquisition”). Creso Pharma is a global medicinal cannabis company that specializes in research, development and production of therapeutic, nutraceutical and animal health products. PharmaCielo will pay A$0.63 per Creso Pharma share, representing a premium of 50% over the closing trading price of the Creso Pharma shares on May 31, 2019. The purchase price for the Creso Pharma shares will be satisfied by the issuance of PharmaCielo common shares (“PharmaCielo Shares”) priced at C$7.6166 per PharmaCielo Share being the 3-day volume weighted average trading price for the PharmaCielo Shares representing an exchange ratio of a 0.0775 PharmaCielo Shares per each Creso Pharma share.
Technology Leader Leverages its Proprietary Data to Provide Evidence-based Research Reports to the Cannabis Industry